Ulcerative Colitis Market

Global Ulcerative Colitis Market Size (2023 to 2028)

The global ulcerative colitis market was valued at USD 6.18 billion in 2023. It is further projected to grow at a CAGR of 6.7% and be worth USD 8.55 billion by 2028.

Ulcerative colitis is an inflammatory bowel disease that can cause ulcers in the larger intestine, irritation, and inflammation. The primary cause of the disease is a dysfunctional immune system failing white blood cells; due to ulcerative colitis, the white blood cells start attacking the colon's lining, leading to severe inflammation and ulcers. Ulcerative colitis does not have a complete cure, but the disease can be controlled by taking proper treatments at regular intervals.

MARKET DRIVERS:

The growing patient population of ulcerative colitis primarily drives the market growth. The prevalence of ulcerative colitis has been growing continuously over the last few years and is expected to grow significantly in the coming years. Factors such as changes in lifestyle, dietary habits, environmental factors, genetic predisposition, increasing awareness, and diagnosis rates result in the increasing incidence of ulcerative colitis. As per the statistics published by the Crohn's & Colitis Foundation, approximately 1.6 million Americans suffer from inflammatory bowel disease, including ulcerative colitis. The growing patient population of ulcerative colitis is driving the demand for diagnostic tests, medical devices, and surgical procedures and offering new opportunities for companies operating in the market.

The growing healthcare expenditure for chronic diseases is another key factor propelling the market growth. Ulcerative colitis is a chronic disease. People suffering from chronic diseases must require long-term management and regular medical care. The costs incurred for the treatment of chronic diseases are significant and are growing with time. The growing number of advancements in diagnostic techniques and tools, such as endoscopy, colonoscopy, and biomarker testing for the diagnosis and treatment of ulcerative colitis promotes the market growth. The rising awareness among patients, healthcare professionals, and the general population about ulcerative colitis and its symptoms favors market growth. Governmental and non-governmental organizations have been taking several awareness campaigns and educational initiatives to increase the awareness levels of people regarding ulcerative colitis.

The rising focus of pharmaceutical companies on the R&D to develop novel therapies for ulcerative colitis, growing healthcare spending particularly in developed countries, the favorable regulatory environment for the approval of new therapies targeting ulcerative colitis, the growing aging population that is more susceptible to developing ulcerative colitis contributes to the market growth. The rising incidence of IBD worldwide, an increasing number of collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers to develop advanced treatment options for ulcerative colitis, the rising shift towards personalized medicine, growing investments from the governments to better the healthcare infrastructure including hospitals, clinics, and specialized treatment centers and the rising focus of key market participants on capturing the potential of emerging markets such as the Asia-Pacific, Latin America and the Middle East further support the market growth.

MARKET RESTRAINTS:

The stringent approval process for biosimilars is the primary factor restraining the growth of the global ulcerative colitis market. Unfavorable rules and policies and Varying conditions in different countries also limit the growth of the ulcerative colitis market. Patent expiration of blockbuster drugs is expected to slow down the growth pace of the ulcerative colitis market during the forecast period. In addition, some of the side effects of the drugs, such as Nausea, Diarrhoea, fever, and headache, is the factor that restrains the market growth.

Impact of COVID-19 on the global ulcerative colitis market:

The COVID-19 impact has shared an unfavorable impact on the ulcerative colitis market. The disruption in routine medical care and non-emergency procedures caused by the COVID-19 pandemic has resulted in delayed diagnoses and treatment initiation for people suffering from ulcerative colitis. Access to diagnostic tests, endoscopy procedures, and in-person appointments with healthcare providers has been limited during the COVID-19 pandemic. Patients with ulcerative colitis hesitated to visit healthcare facilities for treatment during the COVID-19 pandemic due to the fear of contracting with coronavirus. The COVID-19 pandemic has also shown a significant impact on clinical trials and delayed the process of development of novel therapies for ulcerative colitis. Likewise, the COVID-19 pandemic impacted the ulcerative colitis market negatively. On the other hand, the usage of telemedicine and medical care has increased and satisfied the needs of a limited patient population with ulcerative colitis. However, the global ulcerative colitis market is expected to recover quickly and is estimated to grow at a healthy CAGR during the forecast period.

REPORT COVERAGE:

This research report on the global ulcerative colitis market has been segmented and sub-segmented into the following categories.

Ulcerative Colitis Market - By Product:

• Monoclonal Antibodies
• Biosimilars
• Pharmaceuticals

Based on the product, the biosimilars segment held the largest share of the global ulcerative colitis market in 2022 and is anticipated to register a healthy CAGR during the forecast period. The cost-effectiveness of biosimilars and as alternatives to branded biologics, including monoclonal antibodies is one of the key factors propelling segmental growth. The expiration of patents for original biologics, increasing support from regulatory bodies such as the U.S. FDA and the European Medicines Agency for biosimilars, and the growing use of biosimilars to treat inflammatory diseases, including ulcerative colitis, further contribute to the segmental growth.

The monoclonal antibodies segment is predicted to witness the fastest-growing CAGR during the forecast period. The high efficacy and targeted approach of monoclonal antibodies to manage ulcerative colitis, the growing prevalence of ulcerative colitis and the increasing number of research and development activities of key market participants to develop novel monoclonal antibodies with improved efficacy and safety profiles majorly drive the segmental growth.

The pharmaceutical segment is estimated to account for a considerable share of the global ulcerative colitis market during the forecast period.

Ulcerative Colitis Market - By Type:

• Proctosigmoiditis
• Ulcerative Proctitis
• Pancolitis
• Left-sided Colitis

Based on type, the proctosigmoiditis segment had the leading share of the global market in 2022 and is expected to grow at a promising growth rate during the forecast period. The growing prevalence of proctosigmoiditis among ulcerative colitis patients, rising awareness and diagnosis rates and the availability of effective treatment options primarily drive the segmental growth. The growing number of advancements in endoscopic procedures and increasing healthcare expenditure further propel segmental growth.

The ulcerative proctitis segment is predicted to register a healthy CAGR during the forecast period. The rising patient awareness and early detection, the development of targeted therapies and supportive reimbursement policies majorly favor the segmental growth.

Ulcerative Colitis Market - By Route of Administration:

• Oral
• Injectable

Based on route of administration, the oral segment held the major share of the global ulcerative colitis market in 2022. The segmental domination is estimated to continue throughout the forecast period. The ease of administration and patient convenience, the availability of oral medications as a first-line treatment option and the rising preference for oral therapies among patients majorly boost the segmental growth. The growing number of oral medications with improved efficacy and safety profiles and the rising focus on personalized medicine and targeted oral treatments further fuel the segment’s growth rate.

The injectable segment is predicted to rise at a steady CAGR during the forecast period owing to the high efficacy and rapid onset of action of injection administration. Injectable medications are often used for moderate to severe ulcerative colitis. The development of biologic therapies administered via injection, increasing focus on patient adherence and healthcare professional administration and growing pipeline of injectable biologics and targeted therapies further drive the segmental growth.

Ulcerative Colitis Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

The North American ulcerative colitis market led the market in 2022. The regional domination is expected to continue during the forecast period due to the increasing patient population of ulcerative colitis in the North American region, the presence of well-established healthcare infrastructure, high healthcare expenditure, and the availability of advanced diagnostic tools and treatment options for ulcerative colitis in North America. The presence of key pharmaceutical companies conducting research and development, favorable reimbursement policies, and high patient awareness further propel the regional market growth. The U.S. held the major share of the North American market in 2022. The domination of the U.S. market in the North American region is expected to continue during the forecast period due to the growing incidence of ulcerative colitis and the presence of key market participants. As per the data published by the Crohn's & Colitis Foundation, approximately 907,000 people in the U.S. suffer from ulcerative colitis. Canada accounted for a considerable share of the North American market in 2022 and is estimated to grow at a healthy CAGR during the forecast period. An estimated 9.8 to 15.6 per 100,000 population suffer from ulcerative colitis in Canada.

The European ulcerative colitis market accounted for the second-largest share of the global market in 2022 and is predicted to grow at a noteworthy CAGR during the forecast period. The growing prevalence of ulcerative colitis, particularly in Western Europe, the increasing number of initiatives of European governments to promote early diagnosis and treatment and the robust regulatory framework supporting the introduction of new therapies boost the European market growth. As per the data published by the Journal of Crohn's and Colitis, 60 to 140 cases per 100,000 population suffer ulcerative colitis in the European region. A strong focus on patient education and awareness campaigns and the growing adoption of biologics and biosimilars for ulcerative colitis management drive the European market growth. Germany captured the major share of the European market in 2022.

The APAC ulcerative colitis market is the most lucrative regional market for ulcerative colitis treatments and is expected to grow at the fastest CAGR during the forecast period. Rapidly growing patient populations with increasing disease prevalence, increasing improvements in healthcare infrastructure, improving access to healthcare and increasing awareness and diagnosis rates in developing countries of the APAC region majorly drive the APAC market growth. Shift towards personalized medicine, targeted therapies, and rising investments in research and development activities in the Asia-Pacific region further promote regional market growth. India occupied the leading share of the APAC market in 2022 and is expected to grow at a healthy CAGR during the forecast period. Among all countries of the Asia-Pacific region, India has the highest prevalence of ulcerative colitis. As per the statistics published by the World Journal of Gastroenterology, an estimated 6 to 23 per 100,000 population suffer from ulcerative colitis in India. Japan held a considerable share of the APAC market in 2022 and is predicted to grow steadily during the forecast period. South Korea and Australia are predicted to witness a healthy CAGR during the forecast period owing to the rapid adoption of biosimilars.

The Latin American ulcerative colitis market accounted for a considerable share of the global market in 2022 and is expected to grow at a healthy CAGR during the forecast period. The growing incidence and prevalence of ulcerative colitis in the Latin American region, the rapid expansion of healthcare coverage and improved access to treatments, growing healthcare expenditure and investments in healthcare infrastructure drive the Latin American market. The adoption of biosimilars as cost-effective alternatives and an increasing number of collaborations between regional and international pharmaceutical companies boost regional market growth. Brazil followed by Mexico held the major share of the Latin American market in 2022.

The MEA ulcerative colitis market occupied a moderate share of the world market in 2022 and is projected to grow steadily during the forecast period due to the rising awareness and diagnosis rates of ulcerative colitis, the growing investments in research and development for new therapies, rising prevalence of ulcerative colitis among the urban population and increasing number of government initiatives to address the burden of inflammatory bowel diseases favor the regional market growth.

KEY MARKET PARTICIPANTS:

Some of the prominent companies leading the global ulcerative colitis market profiled in this report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche, Shire Pharmaceuticals. The ulcerative colitis market comprises several Key companies, such as AbbVie Inc., Merck, Johnson and Johnson, and others. These companies have implemented strategic plans to strengthen their market position, such as mergers, new product launches, acquisitions, and partnerships.

RECENT MARKET DEVELOPMENTS:

• In 2021, InDex Pharmaceuticals Holding AB (publ) partnered with Parexel Biotech to treat moderate to severe left-sided ulcerative colitis.
• In 2019, Salix Pharmaceuticals started working on treating and preventing gastrointestinal diseases, which Bausch Health Companies Inc owns.
• In June 2019, Abbvie Company completed the acquisition of Allergan to expand its product portfolio to offer extensively advanced treatments for patients.
• In May 2018, Takeda Pharmaceutical Company Limited and Shire PLC announced that Takeda had agreed on a proposed offer to acquire all of Shire's outstanding and future common shares. Based on research and studies conducted in 2019, it is evident that the mitochondrial genes and function are reduced in ulcerative colitis patients. The activity of the chain that transports the electrons is compromised.